Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability (2012 - 2026)

Jazz Pharmaceuticals' Non-Current Deferred Tax Liability history runs 15 years deep, the most recent figure standing at $547.7 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 18.35% year-over-year to $547.7 million; the TTM figure through Mar 2026 stood at $547.7 million (down 18.35% YoY), while the FY2025 annual figure was $594.5 million, down 12.15% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $547.7 million, down from $594.5 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $1.2 billion in Q1 2022, with the low at $547.7 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $809.7 million (2024), against an average of $818.0 million.
• Peak annual rise in Non-Current Deferred Tax Liability reached 1011.84% in 2022, while the deepest fall reached 29.76% in 2022.
• Jazz Pharmaceuticals' Non-Current Deferred Tax Liability stood at $944.3 million in 2022, then dropped by 10.23% to $847.7 million in 2023, then decreased by 20.17% to $676.7 million in 2024, then dropped by 12.15% to $594.5 million in 2025, then dropped by 7.87% to $547.7 million in 2026.
• Business Quant data shows JAZZ's Non-Current Deferred Tax Liability at $547.7 million in Q1 2026, $594.5 million in Q4 2025, and $629.0 million in Q3 2025.